MedTrace Logo

Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.

NCT02715492 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-12-27

No results posted yet for this study

Summary

Hepatocellular carcinoma (HCC) is a major health problem worldwide, and most cases are inoperable because of late presentation and underlying cirrhosis. It represents the fifth most common tumor in the world and the third most frequent cause of mortality amongst patients with cancer.

Due to the worldwide difficulties in finding liver for transplantation, hepatic resection (HR) represents the main stay of curative treatment for patients with HCC. Transcatheter arterial chemoembolization (TACE) is widely used as alternative treatments for unresectable HCC or for patients not eligible to be operated on .

TACE also could be an adjuvant therapy for resectable HCC patients after hepatectomy, which could prevent recurrence and improve long-term survival .

Conditions

Interventions

DRUG

LMWH

(Enoxheparin) 1 IU/kg per dose twice daily for 2 weeks from the 1st day of TACE

PROCEDURE

TACE

Trans arterial chemoembolization

Sponsors & Collaborators

  • Sherief Abd-Elsalam

    lead OTHER

Principal Investigators

  • Osama Negm, Prof · Prof. liver diseases-Tanta university

  • Sabry Abou Saif, Ass. Prof. · Ass/ Prof. liver diseases-Tanta university

  • Mohamed El Gharib, Ass. Prof. · Ass. Prof. interventional radiology - Ain-shams university

  • Sherief Abd-Elsalam, Lecturer · MD liver diseases - Tanta university

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-31
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02715492 on ClinicalTrials.gov